ClinicalTrials.gg
CompletedNCT03057977Updated May 18, 2021Results posted

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

A Phase 3 interventional study of Empagliflozin and Placebo in Heart Failure, sponsored by Boehringer Ingelheim. Completed at 520 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Enrollment
3rd of 51
3,730 · median 90
Started
2017
with 8 others
Phase 3
14 of 51
5 open now
Registered
3rd of 51
by date
Lead sponsor
6 of 51
Boehringer Ingelheim

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 3rd largest by enrollment, is one of 9 that started in 2017, is one of 14 in phase 3, and was the 3rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient age >= 18 years at screening. For Japan only: Age >= 20 years at screening
  • Patients with chronic HF (Chronic Heart Failure) (New York Heart Association Classification) class II-IV and reduced EF () (LVEF (Left Ventricular Ejection Fraction) \<=40%) and elevated NT-proBNP (N-terminal of the prohormone brain natriuretic peptide)

    • If EF >= 36% to \<= 40%: NT-proBNP >= 2500 pg/ml or patients without AF (atrial fibrillation/atrial flutter) and NT-proBNP >= 5000 pg/ml for patients with AF
    • If EF >= 31% to \<= 35%: NT-proBNP >= 1000 pg/ml for patients without AF and NT-proBNP >=2000 pg/ml for patients with AF
    • If EF\<= 30%: NT-proBNP >= 600 pg/ml for patients without AF and NT-proBNP >=1200 pg/ml for patients with AF
    • EF ≤ 40% and hospitalization for heart failure in the past 12 months: NTproBNP ≥ 600 pg/ml for patients without AF and NT-proBNP >= 1200 pg/ml for patients with AF
  • Appropriate dose of medical therapy for HF consistent with prevailing local and international CV (Cardiovascular) guidelines, stable for at least 1 week prior to Visit 1
  • Appropriate use of medical devices such as cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international CV guidelines
  • Signed and dated written ICF ( Form)
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or (Transient Ischaemic Attack) in past 90 days prior to Visit 1
  • Heart transplant recipient, or listed for heart transplant
  • Acute decompensated HF
  • Systolic blood pressure (SBP) >= 180 mmHg at Visit 2.
  • Symptomatic hypotension and/or a SBP \< 100 mmHg
  • Indication of liver disease
  • Impaired renal function, defined as (Estimated Glomerular Filtration Rate) \< 20 mL/min/1.73 m2 (CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration Equation)) or requiring dialysis
  • History of ketoacidosis
  • Current use or prior use of a SGLT (Sodium-glucose co-transporter)-2 inhibitor or combined SGLT-1 and 2 inhibitor
  • Currently enrolled in another device or drug study
  • Known allergy or to empagliflozin or other SGLT-2 inhibitors
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Further exclusion criteria apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,730 participants (actual)

Study arms

  • Experimental
    Empagliflozin

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • once daily

    Also known as: JARDIANCE, JARDIANZ, GIBTULIO

  • DrugPlacebo

    once daily

06

What researchers measure

Primary outcomes

  1. Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)

    Time to the first event of adjudicated cardiovascular (CV) death or adjudicated hospitalisation for heart failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

Secondary outcomes

  1. Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)

    Reported is the total number of HHF events (first and recurrent) which occurred. All data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients was used.

    Time frame: From randomisation until completion of the planned treatment phase, up to 1040 days.

  2. eGFR (CKD-EPI) cr Slope of Change From Baseline

    Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) \[mL/min/1.73m2\] slope of change from baseline. Available on-treatment change-from-baseline data were to be used. Patients without on-treatment data after randomisation were not to be included in this analysis. Slope represents the long term effect on eGFR. Timepoints after baseline were included in calculation of slope of change from baseline. Descriptive statistic (mean(standard error)) is reported.

    Time frame: Assessed at baseline, week 4, 12, 32, 52, 76, 100, 124, 148 and at end of treatment (EOT), up to 1040 days.

  3. Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr

    Time to the first event in the composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, or sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

  4. Time to First Adjudicated Hospitalisation for Heart Failure (HHF)

    Time to first adjudicated Hospitalisation for Heart Failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

  5. Time to Adjudicated Cardiovascular (CV) Death

    Time to adjudicated CV (Cardiovascular) death. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

  6. Time to All-cause Mortality

    Time to all-cause mortality. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

  7. Time to Onset of Diabetes Mellitus (DM)

    Time to onset of DM (Glycated haemoglobin (HbA1c) ≥6.5% or as diagnosed by the investigator) in patients with pre-DM (no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of 5.7 to \<6.5%). The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

    Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.

  8. Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52

    Change from baseline in KCCQ (Kansas City cardiomyopathy questionnaire) clinical summary score at Week 52. The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, selfefficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) is imputed at all subsequent scheduled visits after the date of death. Standard error is adjusted standard error. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.

    Time frame: Assessed at baseline, week 12, week 32 and week 52.

  9. Number of All-cause Hospitalizations (First and Recurrent)

    Number of all-cause hospitalizations (first and recurrent).

    Time frame: From randomisation until completion of the planned treatment phase, up to 1040 days.

07

Results

Posted May 18, 2021

Participant flow

A randomised, double-blind trial to demonstrate superiority of empagliflozin versus placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

Discontinuation From Treatment
Participant flow — Discontinuation From Treatment
MilestonePlacebo10 mg Empagliflozin
Started18671863
Treated18631863
Completed13521381
Not completed515482
Withdrew: Withdrawal by subject12492
Withdrew: Lost to follow-up1117
Withdrew: Protocol violation65
Withdrew: Not treated40
Withdrew: Adverse event343337
Withdrew: Reason unknown01
Withdrew: Personal reasons11
Withdrew: Unblinded medication10
Withdrew: Patient received empagliflozin for diabetes11
Withdrew: Principle investigator decision20
Withdrew: Other medical condition (no adverse event)24
Withdrew: Patient moved away/being abroad43
Withdrew: Unable to continue treatment41
Withdrew: Not attending study visit310
Withdrew: Due to covid-19 pandemic14
Withdrew: Patient decision to stop/interrupt medication86
Discontinuation From Trial
Participant flow — Discontinuation From Trial
MilestonePlacebo10 mg Empagliflozin
Started18671863
Treated18631863
Completed18471841
Not completed2022
Withdrew: Lost to follow-up to primary endpoint99
Withdrew: Limited follow-up agreed22
Withdrew: Withdrawal by subject911

Outcome measures

PrimaryTime to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)

Time to the first event of adjudicated cardiovascular (CV) death or adjudicated hospitalisation for heart failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)21.00 (19.13 to 22.96)15.77 (14.19 to 17.44)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.75 · 95.04% CI 0.65 to 0.86Comparison vs. Placebo \[T/P\]
SecondaryOccurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)

Reported is the total number of HHF events (first and recurrent) which occurred. All data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients was used.

Time frame:
From randomisation until completion of the planned treatment phase, up to 1040 days.
Reported as:
Number · HHF events
Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)
HHF eventsPlacebo10 mg Empagliflozin
Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)553388
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Joint frailty model · p = 0.0003 · Hazard ratio (hr): 0.70 · 95.04% CI 0.58 to 0.85HR vs placebo of recurrent HFF
SecondaryeGFR (CKD-EPI) cr Slope of Change From Baseline

Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) \[mL/min/1.73m2\] slope of change from baseline. Available on-treatment change-from-baseline data were to be used. Patients without on-treatment data after randomisation were not to be included in this analysis. Slope represents the long term effect on eGFR. Timepoints after baseline were included in calculation of slope of change from baseline. Descriptive statistic (mean(standard error)) is reported.

Time frame:
Assessed at baseline, week 4, 12, 32, 52, 76, 100, 124, 148 and at end of treatment (EOT), up to 1040 days.
Reported as:
Mean · Milliliter/minute/1.73 meters squared
eGFR (CKD-EPI) cr Slope of Change From Baseline
Milliliter/minute/1.73 meters squaredPlacebo10 mg Empagliflozin
eGFR (CKD-EPI) cr Slope of Change From Baseline-2.278 ± 0.229-0.546 ± 0.227
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Random intercept random coef. model · p = <0.0001 · Treatment by time interaction: 1.733 · 99.9% CI 0.669 to 2.796Empa vs Placebo slope \[/year\]
SecondaryTime to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr

Time to the first event in the composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, or sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr3.07 (2.33 to 3.91)1.56 (1.06 to 2.17)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = 0.0019 · Hazard ratio (hr): 0.50 · 95% CI 0.32 to 0.77Comparison vs. Placebo
SecondaryTime to First Adjudicated Hospitalisation for Heart Failure (HHF)

Time to first adjudicated Hospitalisation for Heart Failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to First Adjudicated Hospitalisation for Heart Failure (HHF)
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to First Adjudicated Hospitalisation for Heart Failure (HHF)15.55 (13.94 to 17.24)10.75 (9.45 to 12.13)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.69 · 95% CI 0.59 to 0.81Comparison vs Placebo
SecondaryTime to Adjudicated Cardiovascular (CV) Death

Time to adjudicated CV (Cardiovascular) death. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to Adjudicated Cardiovascular (CV) Death
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to Adjudicated Cardiovascular (CV) Death8.13 (7.05 to 9.29)7.55 (6.51 to 8.67)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = 0.4133 · Hazard ratio (hr): 0.92 · 95% CI 0.75 to 1.12Comparison vs. Placebo
SecondaryTime to All-cause Mortality

Time to all-cause mortality. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to All-cause Mortality
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to All-cause Mortality10.71 (9.46 to 12.04)10.06 (8.85 to 11.34)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = 0.3536 · Hazard ratio (hr): 0.92 · 95% CI 0.77 to 1.10Comparison vs. placebo
SecondaryTime to Onset of Diabetes Mellitus (DM)

Time to onset of DM (Glycated haemoglobin (HbA1c) ≥6.5% or as diagnosed by the investigator) in patients with pre-DM (no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of 5.7 to \<6.5%). The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.

Time frame:
From randomisation until completion of the planned treatment period, up to 1040 days.
Reported as:
Number · Patients with events/ 100 pt-yrs at risk
Time to Onset of Diabetes Mellitus (DM)
Patients with events/ 100 pt-yrs at riskPlacebo10 mg Empagliflozin
Time to Onset of Diabetes Mellitus (DM)10.62 (8.42 to 13.07)9.31 (7.27 to 11.60)
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Regression, Cox · p = 0.3576 · Hazard ratio (hr): 0.86 · 95% CI 0.62 to 1.19Comparison vs. placebo
SecondaryChange From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52

Change from baseline in KCCQ (Kansas City cardiomyopathy questionnaire) clinical summary score at Week 52. The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, selfefficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) is imputed at all subsequent scheduled visits after the date of death. Standard error is adjusted standard error. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.

Time frame:
Assessed at baseline, week 12, week 32 and week 52.
Reported as:
Least squares mean · Score on a scale
Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52
Score on a scalePlacebo10 mg Empagliflozin
Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52-3.36 ± 0.69-1.30 ± 0.69
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Mixed Model · p = 0.0340 · Difference of adjusted means: 2.06 · 95% CI 0.16 to 3.96Comparison vs. placebo
SecondaryNumber of All-cause Hospitalizations (First and Recurrent)

Number of all-cause hospitalizations (first and recurrent).

Time frame:
From randomisation until completion of the planned treatment phase, up to 1040 days.
Reported as:
Number · Hospitalizations for any cause
Number of All-cause Hospitalizations (First and Recurrent)
Hospitalizations for any causePlacebo10 mg Empagliflozin
Number of All-cause Hospitalizations (First and Recurrent)15701364
Statistical analysis
  • Placebo vs 10 mg Empagliflozin · Joint frailty model · p = 0.0065 · Hazard ratio (hr): 0.85 · 95% CI 0.75 to 0.95Comparison vs. placebo

Adverse events

Collected over From first intake of study medication until end of planned treatment period + 7 days (Residual Effect Period), up to 1047 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo266/1,867 (14.2%)896/1,863 (48.1%)369/1,863 (19.8%)
10 mg Empagliflozin249/1,863 (13.4%)772/1,863 (41.4%)328/1,863 (17.6%)
Most frequent serious events
Showing 10 of 581
Most frequent serious events
EventPlacebo10 mg Empagliflozin
Cardiac failureCardiac disorders444/1863332/1863
PneumoniaInfections and infestations62/186353/1863
Ventricular tachycardiaCardiac disorders37/186355/1863
Acute kidney injuryRenal and urinary disorders55/186335/1863
Atrial fibrillationCardiac disorders44/186324/1863
Cardiac failure congestiveCardiac disorders41/186326/1863
Cardiac failure chronicCardiac disorders32/186318/1863
Cardiac failure acuteCardiac disorders29/186319/1863
DeathGeneral disorders27/186320/1863
Renal impairmentRenal and urinary disorders27/186317/1863
Most frequent other events
Most frequent other events
EventPlacebo10 mg Empagliflozin
HypotensionVascular disorders109/1863120/1863
HyperuricaemiaMetabolism and nutrition disorders115/186363/1863
HyperkalaemiaMetabolism and nutrition disorders109/186399/1863
NasopharyngitisInfections and infestations94/186389/1863

Baseline characteristics

Randomised Set (RS): All randomised patients.

Age, Continuous
Age, Continuous(Years)Placebo10 mg EmpagliflozinTotal
Mean66.5 ± 11.267.2 ± 10.866.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg EmpagliflozinTotal
Female456437893
Male141114262837
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo10 mg EmpagliflozinTotal
Hispanic or Latino6136161229
Not Hispanic or Latino117811642342
Unknown or Not Reported7683159
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo10 mg EmpagliflozinTotal
American Indian or Alaska Native241539
Asian335337672
Native Hawaiian or Other Pacific Islander6814
Black or African American134123257
White130413252629
More than one race332861
Unknown or Not Reported312758
08

Study locations

520 sites
  • La Mesa Cardiac Center
    La Mesa, California 91942, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • VA Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Merced Vein and Vascular Center
    Merced, California 95340, United States
  • University of California Irvine
    Orange, California 92865, United States
  • Covigilant Research, LLC
    Riverside, California 92506, United States
  • University of California
    Torrance, California 90502, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Blue Coast Cardiology
    Vista, California 92083, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Integrated Heart Care
    Boca Raton, Florida 33434, United States
  • Morton Plant Mease Health Care
    Clearwater, Florida 33756, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Integrative Research Associates
    Fort Lauderdale, Florida 33312, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Cardiovascular Research Center of South Florida
    Miami, Florida 33173, United States
  • Peninsula Research, Inc.
    Ormond Beach, Florida 32174, United States
  • Cardiology Consultants, Inc
    Pensacola, Florida 32501, United States
  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
  • Grady Clinical Research Center
    Atlanta, Georgia 30303, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Cardiovascular Group PC
    Lawrenceville, Georgia 30046, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Northwest Heart Clinical Research, LLC
    Arlington Heights, Illinois 60005, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Captain James A. Lovell Federal Health Care Center
    North Chicago, Illinois 60064, United States
  • Rockford Cardiovascular Associates
    Rockford, Illinois 61107, United States
  • Midwest Cardiovascular Research and Education Foundation
    Elkhart, Indiana 46514, United States
  • St. Francis Medical Group-Indiana Heart Physicians, Inc
    Indianapolis, Indiana 46237, United States
  • Reid Hospital
    Richmond, Indiana 47374, United States
  • Beacon Medical Group Clinical Research
    South Bend, Indiana 46601, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • Louisiana Heart Center
    Covington, Louisiana 70433, United States
  • Clinical Trials of America, LLC
    Monroe, Louisiana 71201, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
  • Johns Hopkins University Hospital School of Medicine
    Baltimore, Maryland 21205, United States
  • MedStar Health Research Institute
    Baltimore, Maryland 21237, United States
  • Metropolitan Cardiovascular Consultants
    Beltsville, Maryland 20705, United States
  • Spectrum Clinical Research
    Towson, Maryland 21204, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • East Mountain Medical Associates, PC
    Great Barrington, Massachusetts 01230, United States
  • Alpena General Hospital
    Alpena, Michigan 49707, United States
  • Regions Hospital
    Saint Paul, Minnesota 55101, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • SLHV
    Saint Louis, Missouri 63136, United States
  • Palm Research Center
    Las Vegas, Nevada 89148, United States
  • Advanced Heart Care, LLC
    Bridgewater, New Jersey 08807, United States
  • Cardiac Care and Vascular Medicine, PLLC
    Bronx, New York 10469, United States
  • Trinity Medical WNY, PC
    Cheektowaga, New York 14227, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • Mount Sinai School of Medicine
    Lake Success, New York 11041, United States
  • St. Luke's Roosevelt Hospital
    New York, New York 10025, United States
  • Harlem Cardiology
    New York, New York 10035, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • Kernodle Clinic West
    Burlington, North Carolina 27215, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-5021, United States
  • Novant Health Heart and Vascular Institute
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27609, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Clinical Trials of America, Inc
    Lenoir, North Carolina 28645, United States
  • Rama Research LLC
    Marion, Ohio 43302, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • South Oklahoma Heart Research Group
    Oklahoma City, Oklahoma 73135, United States
  • Doylestown Health Cardiology
    Doylestown, Pennsylvania 18901, United States
  • York Hospital, WellSpan Health
    York, Pennsylvania 17403, United States
  • AnMed Health Clinical Research
    Anderson, South Carolina 29621, United States
  • Ralph H. Johnson VA Medical Center
    Charleston, South Carolina 29401, United States
  • Palmetto Health
    Columbia, South Carolina 29203, United States
  • William Jennings Bryan Dorn VA Medical Center
    Columbia, South Carolina 29209, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Palmetto Research Center, LLC
    Spartanburg, South Carolina 29302, United States
  • Methodist University Hospital
    Memphis, Tennessee 38104, United States
  • Baylor Heart and Vascular Hospital
    Dallas, Texas 75226, United States
  • Soltero Cardiovascular Research Center
    Dallas, Texas 75226, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8837, United States
  • University of North Texas Health Science Center
    Fort Worth, Texas 76107, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • The Heart Hospital
    Plano, Texas 75093, United States
  • Alpine Research Organization
    Farmington, Utah 84025, United States
  • Cardiac Health Management Network, P.C.
    Chester, Virginia 23836, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Roanoke Heart Institute PLC
    Roanoke, Virginia 24014, United States
  • Salem VA Medical Center
    Salem, Virginia 24153, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
  • Hospital Interzonal General de Agudos Dr Jose Penna
    Bahia Blanca, B8001DDU, Argentina
  • Hospital Italiano Regional del Sur, Bahia Blanca
    Bahia Blanca, B8001HXM, Argentina
  • CIPREC
    Caba, C1119ACN, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, C1199ABB, Argentina
  • Consultorios Asociados de Endocrinología e Invest Clínica
    Ciudad Autonoma Buenos Aires, C1425AGC, Argentina
  • Instituto Cardiovascular de Buenos Aires
    Ciudad Autonoma Buenos Aires, C1428ART, Argentina
  • CCBR - Buenos Aires - AR
    Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
  • Centro Médico Viamonte
    Ciudad Autonoma de Bs As, C1120AAC, Argentina

Showing the first 100 of 520 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ferreira JP, Zannad F, Butler J, Filippatos G, Pocock SJ, Brueckmann M, Steubl D, Schueler E, Anker SD, Packer M. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled. JAMA Cardiol. 2022 Nov 1;7(11):1148-1159. doi: 10.1001/jamacardio.2022.2924. Erratum In: JAMA Cardiol. 2022 Nov 1;7(11):1177. doi: 10.1001/jamacardio.2022.4032. PubMed 36129693 ↗
  • Ferreira JP, Zannad F, Butler J, Filipattos G, Ritter I, Schuler E, Kraus BJ, Pocock SJ, Anker SD, Packer M. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J. 2022 Aug 14;43(31):2984-2993. doi: 10.1093/eurheartj/ehac306. Erratum In: Eur Heart J. 2022 Nov 1;43(41):4377. doi: 10.1093/eurheartj/ehac428. PubMed 35687107 ↗
  • Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D, Zeller C, Januzzi JL, Pocock S, Packer M, Anker SD. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022 Mar 29;79(12):1129-1137. doi: 10.1016/j.jacc.2022.01.029. PubMed 35331406 ↗
  • Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, Zeller C, Pocock SJ, Zannad F, Packer M. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022 Apr;24(4):708-715. doi: 10.1002/ejhf.2409. Epub 2022 Jan 9. PubMed 34957660 ↗
  • Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. PubMed 34861154 ↗
  • Ryden L, Ferrannini G. Is the impact of add on heart failure therapy influenced by background therapy? Lancet Diabetes Endocrinol. 2022 Jan;10(1):3-5. doi: 10.1016/S2213-8587(21)00311-9. Epub 2021 Nov 30. No abstract available. PubMed 34861151 ↗
  • Bohm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schuler E, Ponikowski P, Wanner C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. J Am Coll Cardiol. 2021 Sep 28;78(13):1337-1348. doi: 10.1016/j.jacc.2021.07.049. PubMed 34556320 ↗
  • Januzzi JL Jr, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, Ferreira JP, Sattar N, Verma S, Vedin O, Schnee J, Iwata T, Cotton D, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021 Sep 28;78(13):1321-1332. doi: 10.1016/j.jacc.2021.07.046. PubMed 34556318 ↗
  • Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29. PubMed 34459213 ↗
  • Pocock SJ, Ferreira JP, Gregson J, Anker SD, Butler J, Filippatos G, Gollop ND, Iwata T, Brueckmann M, Januzzi JL, Voors AA, Zannad F, Packer M. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J. 2021 Nov 14;42(43):4455-4464. doi: 10.1093/eurheartj/ehab579. PubMed 34423361 ↗
  • Lam CSP, Ferreira JP, Pfarr E, Sim D, Tsutsui H, Anker SD, Butler J, Filippatos G, Pocock SJ, Sattar N, Verma S, Brueckmann M, Schnee J, Cotton D, Zannad F, Packer M. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021 Nov 14;42(43):4442-4451. doi: 10.1093/eurheartj/ehab360. PubMed 34184057 ↗
  • Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Jamal W, Steubl D, Schueler E, Packer M. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021 Mar 23;77(11):1397-1407. doi: 10.1016/j.jacc.2021.01.044. PubMed 33736821 ↗
  • Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021 Mar 23;77(11):1381-1392. doi: 10.1016/j.jacc.2021.01.033. PubMed 33736819 ↗
  • Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Pina IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021 Mar 31;42(13):1203-1212. doi: 10.1093/eurheartj/ehaa1007. PubMed 33420498 ↗
  • Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Bohm M, Ferreira JP, Pocock SJ, Zannad F, Packer M. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11. PubMed 33175585 ↗
  • Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation. 2021 Jan 26;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. Erratum In: Circulation. 2021 Jan 26;143(4):e29. doi: 10.1161/CIR.0000000000000953. PubMed 33095032 ↗
  • Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021 Jan 26;143(4):326-336. doi: 10.1161/CIRCULATIONAHA.120.051783. Epub 2020 Oct 21. Erratum In: Circulation. 2021 Jan 26;143(4):e30. doi: 10.1161/CIR.0000000000000954. PubMed 33081531 ↗
  • Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PubMed 32865377 ↗
  • Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678. PubMed 31081589 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in May 2020, 37 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 37 months is close to that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2017
First posted
Feb 20, 2017
StartActual
Mar 6, 2017
Primary completionActual
May 1, 2020
CompletionActual
May 28, 2020
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03057977
Responsible party
Sponsor
First posted
Feb 20, 2017
Start date
Mar 6, 2017
Primary completion
May 1, 2020
Completion
May 28, 2020
Results posted
May 18, 2021
Last update
May 18, 2021

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion